[go: up one dir, main page]

DE69530763D1 - Antikörper gegen e-selektin - Google Patents

Antikörper gegen e-selektin

Info

Publication number
DE69530763D1
DE69530763D1 DE69530763T DE69530763T DE69530763D1 DE 69530763 D1 DE69530763 D1 DE 69530763D1 DE 69530763 T DE69530763 T DE 69530763T DE 69530763 T DE69530763 T DE 69530763T DE 69530763 D1 DE69530763 D1 DE 69530763D1
Authority
DE
Germany
Prior art keywords
antibodies
selectect
antibodies against
complement
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69530763T
Other languages
English (en)
Other versions
DE69530763T2 (de
Inventor
Raymond John Owens
Martyn Kim Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Original Assignee
Celltech Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9406243A external-priority patent/GB9406243D0/en
Priority claimed from GB9415331A external-priority patent/GB9415331D0/en
Application filed by Celltech Therapeutics Ltd filed Critical Celltech Therapeutics Ltd
Application granted granted Critical
Publication of DE69530763D1 publication Critical patent/DE69530763D1/de
Publication of DE69530763T2 publication Critical patent/DE69530763T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
DE69530763T 1994-03-29 1995-03-28 Antikörper gegen e-selektin Expired - Fee Related DE69530763T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9406243A GB9406243D0 (en) 1994-03-29 1994-03-29 Antibodies
GB9406243 1994-03-29
GB9415331A GB9415331D0 (en) 1994-07-29 1994-07-29 Antibodies
GB9415331 1994-07-29
PCT/GB1995/000692 WO1995026403A1 (en) 1994-03-29 1995-03-28 Antibodies against e-selectin

Publications (2)

Publication Number Publication Date
DE69530763D1 true DE69530763D1 (de) 2003-06-18
DE69530763T2 DE69530763T2 (de) 2004-02-26

Family

ID=26304600

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69530763T Expired - Fee Related DE69530763T2 (de) 1994-03-29 1995-03-28 Antikörper gegen e-selektin

Country Status (10)

Country Link
US (2) US6204007B1 (de)
EP (1) EP0753065B1 (de)
JP (1) JPH09512705A (de)
AT (1) ATE240395T1 (de)
AU (1) AU707440B2 (de)
CA (1) CA2186455A1 (de)
DE (1) DE69530763T2 (de)
GB (1) GB2301366B (de)
NZ (1) NZ282849A (de)
WO (1) WO1995026403A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026403A1 (en) * 1994-03-29 1995-10-05 Celltech Therapeutics Limited Antibodies against e-selectin
US5962424A (en) * 1995-02-21 1999-10-05 Arch Development Corporation Methods and compositions for targeting selectins
WO1996040942A1 (en) * 1995-06-07 1996-12-19 Cytel Corporation Humanized antibodies to e-selectin
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US6797493B2 (en) 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
JP4524181B2 (ja) 2002-05-30 2010-08-11 マクロジェニクス，インコーポレーテッド Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用
EP1565564A4 (de) * 2002-11-27 2006-06-07 Gtc Biotherapeutics Inc In milch stabil produziertemodifizierte antikörper und verfahren zur herstellung davon
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
CN1922316B (zh) 2003-12-25 2011-03-23 协和发酵麒麟株式会社 抗cd40抗体突变体
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
EP2067789A1 (de) * 2004-04-13 2009-06-10 F. Hoffmann-La Roche Ag Antikörper gegen P-Selectin
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US20060020246A1 (en) * 2004-07-22 2006-01-26 Mclucas Bruce Angiographic catheter for uterine artery embolization
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
KR101019525B1 (ko) 2004-11-12 2011-03-07 젠코어 인코포레이티드 ＦcRn에 대한 변경된 결합성을 갖는 Ｆc 변이체
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
WO2006104989A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
US7973136B2 (en) 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies
KR20140133958A (ko) * 2005-10-21 2014-11-20 엘에프비 유에스에이, 인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법
ME01786B (me) 2006-08-14 2014-09-20 Xencor Inc Optimizovana antitela usmerena na cd19
CA2660795C (en) 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
EP2604278B1 (de) 2007-01-11 2017-04-12 Novo Nordisk A/S Antikörper gegen kir, formulierungen und anwendungen davon
JP2010235447A (ja) * 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
AU2008336249B2 (en) 2007-12-10 2015-01-29 The University Of Queensland Treatment and prophylaxis
CA2711843C (en) 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Her-2 diagnostic methods
EP4269443A3 (de) 2007-12-26 2023-12-27 Xencor, Inc. Fc-varianten mit veränderter bindung zu fcrn
EP2279003A4 (de) * 2008-05-01 2013-04-03 Gtc Biotherapeutics Inc Anti-cd137-antikörper als mittel zur behandlung von entzündlichen erkrankungen
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
WO2010083463A1 (en) * 2009-01-15 2010-07-22 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of her-2 expression
ES2535723T3 (es) * 2009-01-15 2015-05-14 Laboratory Corporation Of America Holdings Métodos de determinación de la respuesta del paciente mediante la medición de Her-3
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
WO2012142411A1 (en) * 2011-04-15 2012-10-18 Clavis Pharma Asa Systems and methods for detecting hent1 expression in hematological disorders
UA128626C2 (uk) * 2019-04-23 2024-09-04 Елджі Кем, Лтд. ЗЛИТИЙ ПОЛІПЕПТИД, ЯКИЙ ВКЛЮЧАЄ Fc-ДІЛЯНКУ ІМУНОГЛОБУЛІНУ І GDF15
WO2021148983A1 (en) 2020-01-24 2021-07-29 Pfizer Inc. Anti-e-selectin antibodies, compositions and methods of use
CA3174236A1 (en) 2020-05-22 2021-11-25 Alwin REITER Ace2-fc fusion proteins and uses thereof
CA3193930A1 (en) 2020-10-29 2022-05-05 Formycon Ag Ace2 fusion proteins and uses thereof
WO2022184854A2 (en) 2021-03-03 2022-09-09 Formycon Ag Formulations of ace2 fc fusion proteins
US20250027067A1 (en) 2021-11-24 2025-01-23 Formycon Ag Improved ace2 fusion proteins
WO2023094571A1 (en) 2021-11-25 2023-06-01 Formycon Ag Stabilization of ace2 fusion proteins
CN119421901A (zh) 2022-03-03 2025-02-11 耶鲁大学 人源化3e10抗体、其变体和抗原结合片段
WO2024092038A2 (en) 2022-10-25 2024-05-02 Ablexis, Llc Anti-cd3 antibodies
WO2024107731A2 (en) 2022-11-14 2024-05-23 Ablexis, Llc Anti-pd-l1 antibodies
EP4386084A1 (de) 2022-12-14 2024-06-19 Formycon AG Verbesserte ace2-fusionsproteine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0307434B2 (de) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Geänderte antikörper
AU625613B2 (en) * 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0438312A3 (en) 1990-01-19 1992-07-01 Merck & Co. Inc. Recombinant human anti-cd18 antibodies
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
EP0639224B1 (de) 1992-04-30 2000-06-28 Genentech, Inc. Varianten in den leltin domäne von selektin
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
WO1995026403A1 (en) * 1994-03-29 1995-10-05 Celltech Therapeutics Limited Antibodies against e-selectin

Also Published As

Publication number Publication date
NZ282849A (en) 1998-05-27
GB2301366A (en) 1996-12-04
DE69530763T2 (de) 2004-02-26
ATE240395T1 (de) 2003-05-15
GB2301366B (en) 1998-07-29
JPH09512705A (ja) 1997-12-22
GB9619691D0 (en) 1996-11-06
AU707440B2 (en) 1999-07-08
US6204007B1 (en) 2001-03-20
US6407214B1 (en) 2002-06-18
EP0753065B1 (de) 2003-05-14
EP0753065A1 (de) 1997-01-15
CA2186455A1 (en) 1995-10-05
WO1995026403A1 (en) 1995-10-05
AU2076995A (en) 1995-10-17

Similar Documents

Publication Publication Date Title
DE69530763D1 (de) Antikörper gegen e-selektin
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
GB2364059A (en) Beta-Secretase enzyme compositions and methods
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
TR200003281T2 (tr) CD-23'e karşı antikorlar, bunların türevleri ve terapötik kullanımları.
DK0670735T3 (da) Perifisering af hæmotopoietiske stamceller.
WO2002086443A8 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
ATE197592T1 (de) Monoklonaler antikörper gegen cd44v6
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
YU34196A (sh) Peptidi i jedinjenja koja se vezuju za receptor
DE69738613D1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
NO20004795D0 (no) Peptidbaserte forbindelser
DK0552296T3 (da) Monoklonale antistoffer fra mus
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
ATE449847T1 (de) Hepatitis c rezeptorprotein cd81
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
TR199700963T1 (xx) Kardiyovask�ler hastal�klar�n tedavisi i�in aminotetralin t�revi.
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee